More aggressive protocols for severe acute injuries may use 0.75 to 1.0 mg daily for the first three to five days before tapering to the standard range
Preclinical (mostly rat) studies show BPC-157 acts like a supercharged project manager that: Builds new blood vessels super fast (angiogenesis) It switches on the VEGF system (the same one your body uses to grow new capillaries) and boosts nitric oxide so fresh blood, oxygen, and nutrients flood the injured area
However, no study has demonstrated a pro-tumoral effect of BPC-157, and some work even suggests a protective effect in certain cancer models
The process may take months or longer, and the FDA may ultimately accept, modify, or reject the committees recommendations
The frequency of circulating lymphocytes - total B (CD19 + ) cells, (CD3 + ) T cells, helper (CD4 + ) T cells, cytotoxic (CD8 + ) T cells, and total NK (CD16 + 56 + ) lymphocyte counts - was in the normal range in over half of all CP patients examined ( Figures 6B, HK )
Use the formula: (Desired dose Total peptide in vial) Total BAC water units 100